Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

August 30, 2019

Primary Completion Date

May 31, 2022

Study Completion Date

July 31, 2024

Conditions
Hypertension
Interventions
DRUG

QUARTET LDQT

Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.

DRUG

Candesartan

Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.

Trial Locations (2)

60108

ACCESS Martin T. Russo Family Health Center, Bloomingdale

60609

Ashland Family Health Center, Chicago

All Listed Sponsors
collaborator

ACCESS Community Health Network

OTHER

collaborator

University of Sydney

OTHER

lead

Washington University School of Medicine

OTHER

NCT03640312 - Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension | Biotech Hunter | Biotech Hunter